Urushibara Takashi, Tanabe Nobuhiro, Suda Rika, Kato Fumiaki, Kasai Hajime, Takeuchi Takao, Sekine Ayumi, Nishimura Rintaro, Jujo Takayuki, Sugiura Toshihiko, Shigeta Ayako, Sakao Seiichiro, Kasahara Yasunori, Tatsumi Koichiro
Department of Respirology, Graduate School of Medicine, Chiba University.
Circ J. 2015;79(12):2696-702. doi: 10.1253/circj.CJ-15-0538. Epub 2015 Oct 15.
This study aimed to investigate the predictors of quality of life (QOL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH), changes in QOL after surgical and medical treatments, and the relationship between baseline QOL and survival.
QOL was measured in 128 patients with CTEPH (male/female: 42/86, age: 56±12 years, surgical/medical: 65/63) using the Short-Form 36 (SF-36) questionnaire. Multiple regression analysis showed pulmonary vascular resistance (PVR) and 6-min walking distance (6MWD) were associated with physical functioning (PF) (P<0.01) and physical component summary (PCS) (P<0.01). In the surgical group, 7 subscales and 2 summary scores improved significantly, and in the medical group 6 subscales and the mental component summary, although the change in QOL was greater in the surgical group. The patients in the conventional therapy group with higher PF had significantly better survival than those with lower PF (5-years survival: 89.5% vs. 50.8%, P=0.002). This difference in survival was not observed in the group receiving pulmonary arterial hypertension (PAH)-specific therapy (100% vs. 100%, P=0.746).
PVR and 6MWD were associated with PF or PCS in CTEPH patients. QOL improved after surgical or medical therapy, with a greater change in the surgical group. PAH-specific therapy improved survival in patients with lower PF at diagnosis.
本研究旨在调查慢性血栓栓塞性肺动脉高压(CTEPH)患者生活质量(QOL)的预测因素、手术和药物治疗后QOL的变化,以及基线QOL与生存率之间的关系。
使用简明健康调查问卷(SF-36)对128例CTEPH患者(男/女:42/86,年龄:56±12岁,手术/药物治疗:65/63)的QOL进行测量。多元回归分析显示,肺血管阻力(PVR)和6分钟步行距离(6MWD)与身体功能(PF)(P<0.01)和身体成分总结(PCS)(P<0.01)相关。手术组中,7个分量表和2个总结得分显著改善,药物治疗组中6个分量表和心理成分总结得分有所改善,尽管手术组QOL的变化更大。传统治疗组中PF较高的患者生存率显著高于PF较低的患者(5年生存率:89.5%对50.8%,P=0.002)。在接受肺动脉高压(PAH)特异性治疗的组中未观察到这种生存差异(100%对100%,P=0.746)。
PVR和6MWD与CTEPH患者的PF或PCS相关。手术或药物治疗后QOL有所改善,手术组变化更大。PAH特异性治疗可提高诊断时PF较低患者的生存率。